Company news
Company news from ShareCast
Expanded use of Cosentyx drug sees Novartis raise expectations
(Sharecast News) - Swiss pharmaceutical giant Novartis raised its full-year guidance Tuesday after beating expectations in its first quarter.
The company attributed its performance to increased use of its psoriasis and arthritis drug Cosentyx.
Novartis said it now expected a high-single to low double-digit percentage growth in net sales for 2024, with adjusted operating income projected to rise by a low double-digit to mid-teens percentage.
According to Reuters, the swift uptake of a newly-approved use of Cosentyx, particularly for treating hidradenitis suppurativa, along with the introduction of a new intravenous infusion option, significantly contributed to a surge in demand.
Key growth drivers in the quarter included the firm's heart failure drug Entresto, and multiple sclerosis drug Kesimpta.
Despite Entresto facing patent expiry next year, it was still a significant contributor to the company's revenue for the time being.
Novartis also announced that it would propose Giovanni Caforio, former Bristol Myers Squibb chief executive officer, as the proposed chairman of its board at the 2025 annual shareholders meeting.
The move came after current chairman Joerg Reinhardt said he would not seek reelection after 12 years in office.
Reporting by Josh White for Sharecast.com.
The company attributed its performance to increased use of its psoriasis and arthritis drug Cosentyx.
Novartis said it now expected a high-single to low double-digit percentage growth in net sales for 2024, with adjusted operating income projected to rise by a low double-digit to mid-teens percentage.
According to Reuters, the swift uptake of a newly-approved use of Cosentyx, particularly for treating hidradenitis suppurativa, along with the introduction of a new intravenous infusion option, significantly contributed to a surge in demand.
Key growth drivers in the quarter included the firm's heart failure drug Entresto, and multiple sclerosis drug Kesimpta.
Despite Entresto facing patent expiry next year, it was still a significant contributor to the company's revenue for the time being.
Novartis also announced that it would propose Giovanni Caforio, former Bristol Myers Squibb chief executive officer, as the proposed chairman of its board at the 2025 annual shareholders meeting.
The move came after current chairman Joerg Reinhardt said he would not seek reelection after 12 years in office.
Reporting by Josh White for Sharecast.com.
Important information
Spread Betting and CFD trading carry a high level of risk to your capital; you should ensure you understand the risks involved. Please read the full risk warning.Have a question?
Call us on
0117 988 9915
8.00am to 6.00pm (Monday to Friday)
HL Markets account holders
Call us on
020 7573 0055
Email us
ShareCast
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.Market latest
FTSE 100 | FTSE 250 | All Share
FTSE 100 | 8,213.49 | +0.51% | |
FTSE 250 | 20,164.54 | +0.56% | |
FTSE All Share | 4,469.09 | +0.52% | |
Dow Jones | 38,675.68 | +1.18% | |
NASDAQ | 16,156.33 | +1.99% | |
Xetra DAX | 18,077.11 | +0.42% | |
Paris CAC 40 | 7,979.89 | +0.28% | |
Nikkei 225 | 38,236.07 | -0.10% | |
Hang Seng | 18,578.30 | +0.55% |
Hang Seng disclaimer l Prices delayed by at least 15 minutes